Breaking News
November 21, 2018 - Smoke-free laws associated with reduced systolic blood pressure
November 21, 2018 - Achieving new guideline blood pressure goals may prevent 3 million cardiovascular events
November 21, 2018 - LDR brachytherapy for treating early-stage prostate cancer lacks conclusive data
November 21, 2018 - Purified omega-3 and aspirin reduce pre-cancerous bowel polyps, shows study
November 21, 2018 - Study warns that potential epigenetic therapy may boost lung cancer stem cells
November 21, 2018 - Noise pollution in hospital impact quality and safety of healthcare
November 21, 2018 - Higher Risk for Amputation, DKA With SGLT2 Inhibitors for T2DM
November 21, 2018 - Researchers stop ‘sneaky’ cancer cells in their tracks
November 21, 2018 - People who are afraid to draw their blood over-estimate the risk of fainting
November 21, 2018 - Personalized physical exercise reverses functional, cognitive deterioration in the elderly
November 21, 2018 - COPD linked to obesity in older women who have never smoked
November 21, 2018 - AHA: Cold-Weather Drinks Are Here, But Watch Out for the Calories
November 21, 2018 - Crowds line up at 1st East Coast pot shops
November 21, 2018 - Merck declares 2018 Life Science Award winners
November 21, 2018 - Many people underestimate the impact of sprains, say foot scientists
November 21, 2018 - Lower levels of protein make squamous carcinoma cells more invasive
November 21, 2018 - Study highlights a new predictor of type 2 diabetes
November 21, 2018 - NTU and TTSH join forces to improve doctor-patient communication
November 21, 2018 - New low-cost injectable hydrogel could help wounds heal faster
November 21, 2018 - Merck Announces Winners of 2018 Life Science Awards
November 21, 2018 - Check your medical records for dangerous errors
November 21, 2018 - Amount of weight regain after bariatric surgery helps predict health risks
November 21, 2018 - Heart failure patients with stronger hearts have more depressive symptoms, lower quality of life
November 21, 2018 - Women can be as resilient as men in undertaking arduous physical activity
November 21, 2018 - Receptor structure could be key to developing new osteoporosis drugs
November 21, 2018 - Researchers identify human white matter pathway associated with individual variability in human stereoacuity
November 21, 2018 - Vitamin D critical to early development of vertebrates, study suggests
November 21, 2018 - Myriad biological, societal factors that impact CKD severity for children of African descent
November 21, 2018 - Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer
November 21, 2018 - Experts offer more clarity on managing common ankle fractures
November 21, 2018 - About 300 million bits of DNA are missing from basic reference genome, report scientists
November 21, 2018 - Study explores how the moving brain processes visual information
November 21, 2018 - Biomedical engineers stop cancer cells from moving and spreading
November 21, 2018 - Gut protein mutations protect against spikes in blood glucose levels
November 21, 2018 - First probabilistic atlas of thalamus nuclei to better understand the brain
November 21, 2018 - Peanut allergies could soon have a drug treatment
November 21, 2018 - Vanderbilt researchers isolate antibody that can neutralize West Nile virus
November 21, 2018 - KHN’s ‘What the Health?’ Health nerd books for the holidays
November 21, 2018 - MDMA could help gain trust but does not make one naive find researchers
November 21, 2018 - Study uncovers new mechanism controlling the master cancer regulator
November 21, 2018 - Online communication technologies could stave off depression among seniors, shows study
November 21, 2018 - FDA Approves Gamifant (emapalumab-lzsg) for Primary Hemophagocytic Lymphohistiocytosis
November 21, 2018 - Artificial intelligence predicts treatment effectiveness
November 21, 2018 - A bicyclist’s road to recovery after traumatic brain injury
November 21, 2018 - New research project to combat obesity, type 2 diabetes receives NIH funding
November 21, 2018 - Humans play key role in distribution and transmission of Bartonella bacteria
November 21, 2018 - First modeling system developed for testing age-specific human immune responses to vaccines
November 21, 2018 - FDA Alert: Gilenya (fingolimod): Drug Safety Communication
November 21, 2018 - Uric Acid Test: MedlinePlus Lab Test Information
November 21, 2018 - Researchers use genetics to predict response to antipsychotic medications
November 21, 2018 - Proposal to include the price of drugs in television ads is flawed, Stanford scholar writes
November 21, 2018 - Disrupting reproduction strategy of disease-causing parasites could help fight malaria
November 20, 2018 - ACAAI: Almost 2 Percent of Children Have Milk Allergy
November 20, 2018 - Congenital anomalies of kidney and urinary tract – Genetics Home Reference
November 20, 2018 - Can video games improve the health of older adults with schizophrenia?
November 20, 2018 - Can flicking a molecular switch restore the aging immune system’s competence?
November 20, 2018 - Restek launches new Oregon cannabis pesticide standards
November 20, 2018 - Health sector coalition urges Government to safeguard patients in future UK-EU relationship
November 20, 2018 - Study evaluates second-hand marijuana smoke exposure among children
November 20, 2018 - Scientists identify three genes responsible for recurrent molar pregnancies
November 20, 2018 - Researchers identify multisystem disorder caused by bi-allelic variants in CCDC47 gene
November 20, 2018 - Dining Out With Allergies Is Tough, But These Steps Can Help
November 20, 2018 - Breastfeeding protects infants from antibiotic-resistant bacteria
November 20, 2018 - AI matched, outperformed radiologists in screening X-rays for certain diseases | News Center
November 20, 2018 - Adolescents increasingly choose marijuana over cigarettes, alcohol
November 20, 2018 - World’s first medical imaging scanner produces diagnostic scan of the whole human body
November 20, 2018 - Cytocybernetics receives NIMH award to move into neuronal drug development
November 20, 2018 - Researchers discover new information on pathological mechanisms of Alzheimer’s disease
November 20, 2018 - ‘Unknown’ enzyme may be key to new treatment for inflammatory diseases
November 20, 2018 - Recreational drug may help people regain trust in others
November 20, 2018 - Researchers identify gene vital for post-stroke recovery
November 20, 2018 - Scientists identify novel target for neuron regeneration, functional recovery in spinal cord injury
November 20, 2018 - Potential new therapeutic approach developed for synovial sarcoma
November 20, 2018 - Skeletal imitation reveals how bones grow atom-by-atom
November 20, 2018 - Autism behaviors show unique brain network fingerprints in infants
November 20, 2018 - Location matters for inflammation clearance
November 20, 2018 - Towards finding a druggable cancer target
November 20, 2018 - Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019
November 20, 2018 - Cooling ‘brains on fire’ to treat Parkinson’s
November 20, 2018 - Less pollution could increase the average lifespan of Copenhageners by an entire year in 2040
Researchers develop new approach to assess effectiveness of Men B vaccine

Researchers develop new approach to assess effectiveness of Men B vaccine

image_pdfDownload PDFimage_print

Researchers at the University of Leicester and Meningococcal Reference Unit have developed a new approach to assess the effectiveness of the Men B vaccine, Bexsero®, against different strains that cause meningococcal meningitis and septicemia.

The new approach allows direct testing of blood samples from patients with meningococcal disease to find out if the strain they are infected with might have been prevented by the vaccine. Currently, it is estimated that the vaccine offers protection against 73-88% of strains responsible for meningococcal disease in England and Wales.

The approach is being assessed by Public Health England for its potential to routinely test all meningococcal disease cases.

The research was based on looking at one of the four antigens that make up the vaccine. More work is needed to look at the remaining three antigens.

Dr Chris Bayliss, from the University of Leicester’s Department of Genetics and Genome Biology, said: “This new research fills a gap in current testing capabilities that determine whether a disease-causing meningococcal strain is expected to be covered by the vaccine.

“We are currently unable to obtain and grow live bacteria from up to half of patients to determine whether the vaccine might have prevented the type of meningococcal disease they have, often because treatment with antibiotics has already killed them. There is a need for new tests to identify and measure the amount of antigen by obtaining meningococcal DNA directly from patient samples.”

Bexsero® is a vaccine that helps protect against group B meningococcal disease (MenB), developed by GSK. It was introduced into the UK infant immunization schedule in September 2015 and has been shown to be highly effective in preventing MenB disease in vaccinated infants.

One of the protective components of Bexsero® is an antigen called factor H binding protein (fHbp). Infants vaccinated with MenB vaccines produce antibodies against this protein, so that if they are exposed to meningococcal bacteria that possess this protein, these antibodies will kill the bacteria.

In a study published in the academic journal PLOS ONE, funded by Meningitis Research Foundation (MRF), the researchers show how a combination of DNA sequences and statistical testing can be used to measure the amounts of fHbp present in disease-causing meningococcal bacteria.

Researchers and Mathematicians at the University of Leicester studied more than 2,000 disease-causing meningococcal isolates to measure how much antigen each strain produces.

They used their results to categorize each strain into three classes: ‘covered’; ‘not covered’; and ‘at risk’. The ‘not covered’ groups included the ~12% of strains that will not be covered by the vaccine while the ‘at risk’ groups contains strains that are more likely to cause illness in vaccinated individuals.

Dr Bayliss said: “Detailed molecular analyses of clinical samples are essential for understanding how efficient the new vaccines against meningococcal disease are at protecting people against different meningococcal strains.

“This novel approach has the potential to help measure the effectiveness of Bexsero® more accurately.

“The detailed information collected on the fHbp protein could be important in helping to improve the next generation of MenB vaccines.”

Linda Glennie, Director of Research at MRF, said: “Introducing the MenB vaccine into the UK immunization schedule in 2015 was a major step forward. Vaccines are the only way to prevent bacterial meningitis and septicemia. The MenB vaccine has already been proven to be safe and effective and rates of MenB have been reducing since the introduction of the vaccine. Now that we have a vaccine in the schedule that gives good protection against MenB, these new testing techniques that the scientists have developed will give us crucial insights. Over the years, the strains that circulate in the UK have changed, and it is important to be certain about how much coverage the current MenB vaccines can provide, both now and in the future.”

“We are very encouraged by the results of the study , though measuring the attribution of only one antigen, fHbp, alone, without taking the effect of the other three components of Bexsero into consideration, may underestimate its protective effect,” said Rafik Bekkat-Berkani,MD. Global Medical Affairs Lead from GSK. “Bexsero’s 4 distinct components target different mechanisms in MenB survival and disease development and offer the potential to protect against invasive MenB strains even when the expression of one component is low or antigenically different. We agree with the study’s authors that more research is needed on Bexsero’s additional three antigens potentially providing multiple targets for vaccine-induced antibodies.”

Shamez Ladhani, Paediatric Infectious Disease Consultant, Public Health England, said: “Since the introduction of the MenB vaccine program in 2015, cases of Meningococcal B disease have nearly halved in infants under 1 year and in one and two year olds, who became eligible for the 12-month booster in May 2016. However, any case of meningococcal disease is tragic and, unfortunately, not all cases of meningitis and septicemia are preventable through vaccines. This research is important in helping us understand how we can best protect those who are most at risk from a very serious disease.”

Source:

https://www2.le.ac.uk/news/blog/2018-archive/june/new-way-to-determine-protection-of-men-b-vaccine-against-different-strains

About author

Related Articles